At a glance
- Originator Aventis
- Class Antineoplastics
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 22 Dec 1999 Hoechst Marion Roussel has merged with Rhône-Poulenc Rorer to form Aventis Pharma
- 08 Nov 1999 New profile
- 08 Nov 1999 Preclinical development for Cancer in USA (Unknown route)